DADA2 Foundation Officially Formed
By Spring 2016, the DADA2 Foundation was officially incorporated as a 501(c)(3) in the US.
Read MoreInformal Gathering on DADA2 at CIS in Houston
Dr. Chambers organizes meeting of just seven immunologists and related specialists while they all gathered at the Clinical Immunology Society meeting in Houston. They discussed known data on DADA2 and formulated questions around uncertainties. At this meeting, it was determined a larger meeting could happen on the disease.
Read MoreADA2 Name adopted
HUGO Gene Nomenclature agreed to change CECR1 to the ADA2 gene and approved the name “Adenosine Deaminase 2”. Pictured above is the ADA2 protein scientific ribbon model.
Read More3rd International Patient Conference Held – Virtual
Due to the ongoing Covid-19 pandemic, we held a virtual conference for patients, which brought more than 100 patients and their family members together for a day-long summit on the latest with DADA2. You can watch the Conference Videos on our YouTube Channel: https://www.youtube.com/@dada2foundation/playlists .
Read More3rd International Scientific Conference on DADA2 – Virtual
Due to the Covid-19 pandemic, we held our 3rd International Conference in a virtual format. More than 500 physicians and researchers from around the globe registered, and on any given day throughout the 3-day conference, more than 300 attended the conference from 30+ countries. Watch the Conference Videos here: https://www.youtube.com/@dada2foundation/playlists
Read MoreADA2 Point of Care Testing Device in Development
DADA2 Foundation initiates research and supported the development of the ADA2 Now Point of Care Testing Device, which can identify a DADA2 patient in as little as 30 minutes.
Read MoreConsensus Statement Published
Published the world’s only and first Consensus Statement alongside 35 researchers & physicians and 3 patients in the Journal of the American Medical Association Network Open Access.
Read MorePrevalence Study Published
The DADA2 Foundation, Boston Children’s Hospital and MIT/Broad Institute study suggests that the carrier frequency of deleterious ADA2 variants is approximately 1 in 236 individuals, which translates into an estimated disease prevalence of 1 case per 222 000 individuals. This could suggest potentially 35,000 patients globally if fully diagnosed.
Read MoreHistory of DADA2 Video Published
The DADA2 Foundation publishes A History of the DADA2 Foundation.
Read MoreDADA2 Joins Chan Zuckerberg Initiative Inaugural Rare as One Cohort
Chan Zuckerburg Initiative chooses DADA2 Foundation for the inaugural cohort of the Rare As One Project – which invests grant funds in capacity building for patient-driven rare disease foundations.
Read More